



1625

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		Docket Number: 1662/52602	
Application Number 09/841,025	Filing Date April 24, 2001	Examiner Chang, Celia C.	Art Unit 1625
Invention Title ZOLPIDEM HEMITARTRATE		Inventor(s) Judith Aronhime et al.	

Address to:
Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop: Amendment
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on

Date: 4/28/06

Signature: Agnes Xu
Agnes Xu

Sir:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. The references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each non-U.S. patent, non-U.S. published application, unpublished U.S. application, non-patent publication, or other information listed on the PTO form 1449 is enclosed.
4. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a final action, Notice of Allowance, or any action that otherwise closes prosecution.
5. Please debit Deposit Account No. **11-0600** in the amount of **\$180.00** in payment of the fee under 37 CFR § 1.17(p) to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached. 37 CFR § 1.97(c)(2).

Dated: 4/28/06

By:

Craig L. Puckett

Craig L. Puckett (Reg. No. 43,023)

KENYON & KENYON LLP

One Broadway

New York, New York 10004

(212) 425-7200 (telephone)

(212) 425-5288 (facsimile)

CUSTOMER NUMBER 26646

05/03/2006 JBALINAN 00000019 110600 09841025

01 FC:1806

180.00 DA



	DOCKET NO. 1662/52602	SERIAL NO. 09/841,025
INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449	APPLICANT Judith Aronhime et al.	
	FILING DATE April 24, 2001	GROUP 1625

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT/PUBLICATION NUMBER	PATENT/PUBLICATION DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						Yes	No
	EP 1 104 765 A2	June 6, 2001	EP				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.	
	Dunitz, J.D. and Bernstein, J.; "Disappearing Polymorphs", <i>Acc.Chem.Res.</i> 1995 , 28, 193-200	
	Byrn, S.R.; "Solid-State Chemistry of Drugs", Academic Press, 1982, P. 3-26	
	Byrn, S.R., et al.; "Solid-State Pharmaceutical Chemistry", <i>Chem.Mater.</i> , 1994 , 6, 1148-1158	
	Bernstein, J.; "Polymorphism in Molecular Crystals", Clarendon Press, 2002, Page 9	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	